{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-092064","form_type":"8-K","ticker":"CYRX","cik":"0001124524","company_name":"Cryoport, Inc.","filed_at":"2026-08-06T20:30:48+00:00","discovered_at":"2026-08-06T20:33:04.409038+00:00","generated_at":"2026-08-06T20:33:26.205458+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cryoport Q2 2026 revenue $49.0M (+8% YoY); achieves positive adjusted EBITDA","bullets":["Revenue $49.0M, up 8% YoY; Life Sciences Services +15%, BioStorage/BioServices +25%.","Adjusted EBITDA from continuing operations positive $0.4M vs -$0.9M in Q2 2025.","Net loss attributable to common stockholders $0.20 per share (vs $2.13 income in Q2 2025, which included divestiture gain).","Supporting 779 clinical trials and 22 commercial CGT as of June 30, 2026.","Cash and short-term investments $396.7M; anticipate 11 possible BLA/MAA applications in H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-092064","json":"https://secwatch.observer/filing/0001104659-26-092064.json","markdown":"https://secwatch.observer/filing/0001104659-26-092064.md","text":"https://secwatch.observer/filing/0001104659-26-092064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124524/000110465926092064/0001104659-26-092064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124524/000110465926092064/tm2622464d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:33:26.205458+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}